Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024;16(15):791-800.
doi: 10.1080/17576180.2024.2368339. Epub 2024 Jul 23.

Bioanalysis of free antisense oligonucleotide payload from antibody-oligonucleotide conjugate by hybridization LC-MS/MS

Affiliations

Bioanalysis of free antisense oligonucleotide payload from antibody-oligonucleotide conjugate by hybridization LC-MS/MS

Di Jiang et al. Bioanalysis. 2024.

Abstract

Background: Antisense oligonucleotides (ASOs) have been conjugated to various moieties, such as peptides, antibodies or Fab regions of antibodies, to enhance their delivery to target tissues. The quantitation of free ASO (ASO payload) is critical to characterize its pharmacokinetics/pharmacodynamics (PK/PD) properties and biodistribution after delivery of the peptide/antibody/Fab ASO conjugates.Results: We developed a hybridization-based LC-MS/MS methodology for quantification of free ASO in tissues in the presence of Fab-ASO and ASO with linker (ASO-linker).Conclusion: The developed method was applied to measure accurately the free ASO concentrations in liver and gastrocnemius in mice that were dosed with Fab-ASO. This methodology has also been applied to free ASO bioanalysis for other antibody-ASO and Fab-ASO conjugates in various tissues and plasma/serum samples.

Keywords: Fab–ASO conjugates; LC-MS/MS; antibody–ASO conjugates; antibody–oligonucleotide conjugates (AOCs); antisense oligonucleotides (ASOs); bioanalysis; hybridization.

Plain language summary

[Box: see text].

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, stock ownership or options and expert testimony.

Figures

Figure 1.
Figure 1.
Scheme of ASO1, ASO1-linker and Fab–ASO1.
Figure 2.
Figure 2.
Effect of proteinase K digestion and hybridization extraction on Fab–ASO1 and ASO1-linker. (A) Peak area of ASO1 in Fab–ASO1 and ASO1-linker with no treatment, hybridization only and proteinase K digestion followed by hybridization; (B) Peak area of ASO1-linker in Fab–ASO1 and ASO1-linker with no treatment, hybridization only and proteinase K digestion followed by hybridization.
Figure 3.
Figure 3.
Recovery of ASO1 in mouse plasma and brain homogenate at different MRDs.
Figure 4.
Figure 4.
LC-MS/MS chromatograms of ASO1 and the IS, ASO-IS from (A) double blank, (B) blank spiked with ASO-IS only, (C) LLOQ and (D) ULOQ in mouse liver and gastrocnemius combine homogenate. IS: Internal standard; LLOQ: Lower limit of quantitation; ULOQ: Upper limit of quantitation.

Similar articles

Cited by

References

    1. Rinaldi C, Wood MJA. Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol. 2018;14(1):9–21. doi:10.1038/nrneurol.2017.148 - DOI - PubMed
    1. Dhuri K, Bechtold C, Quijano E, et al. . Antisense oligonucleotides: an emerging area in drug discovery and development. J Clin Med. 2020;9(6):2004. doi:10.3390/jcm9062004 - DOI - PMC - PubMed
    1. Moumné L, Marie A-C, Crouvezier N. Oligonucleotide therapeutics: from discovery and development to pPatentability. Pharmaceutics. 2022;14(2):260. doi:10.3390/pharmaceutics14020260 - DOI - PMC - PubMed
    1. Crooke ST, Baker BF, Crooke RM, et al. . Antisense technology: an overview and prospectus. Nat Rev Drug Discov. 2021;20(6):427–453. doi:10.1038/s41573-021-00162-z - DOI - PubMed
    1. Krychtiuk KA, Rader DJ, Granger CB. RNA-targeted therapeutics in cardiovascular disease: the time is now. Eur Heart J Cardiovasc Pharmacother. 2022;9(1):94–99. doi:10.1093/ehjcvp/pvac052 - DOI - PubMed

MeSH terms

LinkOut - more resources